Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seraprevir + Sofosbuvir in HCV Genotype 2, 3, 6
NCT04111367Phase 2Unknown
- Sponsor
- Ginkgo Bioworks
- Start
- Apr 2019
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of seraprevir in hepatitis C (HCV) (2 arms), sponsored by Ginkgo Bioworks. Primary endpoint: Sustained Virologic Response 12 Weeks After End of Treatment. Status: unknown.
02
Drugs
seraprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT04111367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04111367.